natgillin/translations-raw huggingface dataset:
Diabetes Mellitus (IRMA 2)” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria. 
Klinička studija „Učinak irbesartana na mikroalbuminuriju u hipertenzivnih bolesnika sa šećernom bolesti tipa 2 (IRMA 2)“ pokazuje da 300 mg irbesartana odgađa progresiju izražene proteinurije u bolesnika s mikroalbuminurijom.
No dosage adjustment is necessary in female patients. 
Stoga, nije potrebna prilagodba doziranja u žena.
Common (may affect up to 1in 10 people): dizziness, feeling sick/vomiting, fatigue and blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase enzyme). 
Često (mogu se javiti u manje od 1 na 10 osoba): omaglica, mučnina/povraćanje, umor i krvne pretrage mogu pokazati povišenu razinu enzima specifičnog za mišićnu i srčanu funkciju (enzim kreatinin kinaza).
Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as needed to help achieve the blood pressure goal. 
Dodatni antihipertenzivi (isključujući ACE inhibitore, antagoniste receptora angiotenzina II i dihidropiridinske blokatore kalcijevih kanala)
In the female and black subgroups which represented 32 % and 26 % of the overall study population respectively, a renal benefit was not evident, although the confidence intervals do not exclude it. As for the secondary endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups in the overall population, although an increased incidence of non-fatal MI was seen for women and a decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebobased regimen. 
Za sekundarni studijski ishod fatalnih i nefatalnih kardiovaskularnih događaja, u sveukupnoj ispitivanoj populaciji nije bilo razlika između tri skupine, iako je zabilježena povećana incidencija nefatalnog infarkta miokarda u žena i smanjena incidencija nefatalnog infarkta miokarda u muškaraca u skupini koja je primala irbesartan u odnosu na onu koja je primala placebo.
Exposure to AIIRAs therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). 
Poznato je da u ljudi terapija antagonistima receptora angiotenzina II tijekom drugog i trećeg tromjesečja izaziva fetotoksičnost (smanjena bubrežna funkcija, oligohidramnion, usporavanje okoštavanja lubanje) i neonatalnu toksičnost (zatajenje bubrega, hipotenzija, hiperkalijemija) (vidjeti dio 5.3.).
White to off white capsule shaped, film coated tablet. 
Bijela do gotovo bijela, filmom obložena tableta u obliku kapsule.
Irbesartan Teva is available in pack sizes of 7, 14, 28, 30, 56, 60, 80, 84, 90, 98 and 100 film-coated tablets in non-perforated blisters; pack sizes of 50 x 1 and 56 x 1 film-coated tablet in unit dose blisters and pack size of 28 film-coated tablets in non-perforated calendar blisters. 
Irbesartan Teva dostupan je u pakiranjima sa 7, 14, 28, 30, 56, 60, 80, 84, 90, 98 i 100 filmom obloženih tableta u neperforiranim blisterima; pakovanjima sa 50 x 1 i 56 x 1 filmom obloženom tabletom u blisterima djeljivim na jedinične doze i pakiranju sa 28 filmom obloženih tableta u neperforiranim kalendarskim blisterima.
The demonstration of renal benefit of irbesartan in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1). 
zasniva se na ispitivanjima u kojima se irbesartan prema potrebi uzimao kao dopuna ostaloj antihipertenzivnoj terapiji za postizanje ciljnog krvnog tlaka (vidjeti dijelove 4.3, 4.4, 4.5 i 5.1).
if you get excessive vomiting or diarrhoea if you suffer from kidney problems if you suffer from heart problems if you receive Irbesartan Teva for diabetic kidney disease. 
Obratite se svom liječniku prije nego uzmete Irbesartan Teva i ako se nešto od dolje navedenog odnosi na Vas: ako Vas muči prekomjerno povraćanje ili proljev ako imate problema s bubrezima ako imate srčanih problema ako uzimate Irbesartan Teva zbog dijabetičke bolesti bubrega.
The usual dose is 150 mg once a day. 
Bolesnici s visokim krvnim tlakom Uobičajena doza iznosi 150 mg jednom na dan.
The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4). 
Uzimanje antagonista receptora angiotenzina II ne preporučuje se tijekom prvog tromjesečja trudnoće (vidjeti dio 4.4.), a kontraindicirana je tijekom drugog i trećeg tromjesečja (vidjeti dio 4.3. i 4.4.).
Not known: impaired renal function including cases of renal failure in patients at risk (see section 4.4) Reproductive system and breast disorders 
oštećena funkcija bubrega, uključujući slučajeve zatajenja bubrega u rizičnoj skupini bolesnika (vidjeti dio 4.4).
Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. 
Osim ako se nastavak terapije antagonistima receptora angiotenzina II ne smatra neophodnim, bolesnice koje planiraju trudnoću trebaju prijeći na alternativnu antihipertenzivnu terapiju s potvrđenom sigurnošću primjene u trudnoći.
Irbesartan Teva 150 mg film-coated tablets EU/1/09/576/014 7 tablets 
Irbesartan Teva 150 mg filmom obložene tablete EU/1/09/576/014 7 tableta
The efficacy of irbesartan is not influenced by age or gender. 
Dob i spol ne utječu na djelotvornost irbesartana.
if you are taking any of the following medicines used to treat high blood pressure: - an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems - aliskiren 
ako uzimate bilo koji od lijekova navedenih u nastavku, koji se koriste za liječenje visokog krvnog tlaka: - blokator angiotenzin II receptora (ARB) (nazivaju se i sartanima - primjerice valsartan, telmisartan, irbesartan), osobito ako imate bubrežne tegobe povezane sa šećernom bolešću
Irbesartan Teva 75 mg film-coated tablets EU/1/09/576/001 7 tablets 
Irbesartan Teva 75 mg filmom obložene tablete EU/1/09/576/001 7 tableta
Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. 
Tijekom istodobne primjene litija i inhibitora angiotenzin konvertirajućeg enzima zabilježen je reverzibilan porast koncentracije serumskog litija i njegove toksičnosti.
Studies have not been performed in patients with severe hepatic impairment. 
Nisu provođena ispitivanja kod bolesnika s teškim oštećenjem funkcije jetre.
The study of the “Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 
Dokaz koristi irbesartana na bubrežnu funkciju u hipertenzivnih bolesnika sa šećernom bolesti tipa 2
• Each Irbesartan Teva 75 mg film-coated tablet contains 75 mg irbesartan. 
• Jedna Irbesartan Teva 75 mg filmom obložena tableta sadrži 75 mg irbesartana.
In 1.7 % of hypertensive patients with advanced diabetic renal disease treated with irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been observed. 
Smanjenje razine hemoglobina*, koje nije bilo klinički značajno, zabilježeno je u 1,7% hipertenzivnih bolesnika s uznapredovalom dijabetičkom bubrežnom bolesti koji su primali irbesartan.
The decrease in blood pressure is dose-related for once a day doses with a tendency towards plateau at doses above 300 mg. Doses of 150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo. 
150-300 mg jedanput na dan smanjuju krvni tlak u ležećem ili sjedećem položaju u vrijeme najniže koncentracije u krvi (to jest 24 sata nakon uzimanja doze) i to u prosjeku za 8-13/5-8 mm Hg
• Each Irbesartan Teva 150 mg film-coated tablet contains 150 mg irbesartan. 
• Jedna Irbesartan Teva 150 mg filmom obložena tableta sadrži 150 mg irbesartana.
Teva UK Limited Tel: +44 1977628500 
Tel: +44 1977628500
However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years. 
Međutim, u hemodijaliziranih bolesnika i u bolesnika starijih od 75 godina može se razmotriti započinjanje terapije dozom od 75 mg.
Hepatic impairment 
anafilaktički šok
After either oral or IV administration of 14C irbesartan, about 20 % of the radioactivity is recovered in the urine, and the remainder in the faeces. 
irbesartana, oko 20% radioaktivnosti pojavilo se u mokraći, a ostatak u stolici.
• Each Irbesartan Teva 300 mg film-coated tablet contains 300 mg irbesartan. 
• Jedna Irbesartan Teva 300 mg filmom obložena tableta sadrži 300 mg irbesartana.
The other side of the tablet debossed with number “7466”. 
Na drugoj strani tablete je utisnut broj “7466”.
The other side of the tablet debossed with number “7464”. 
Na drugoj strani tablete je utisnut broj "7464".
nausea/vomiting 
proljeva ili povraćanja.
Irbesartan 150 mg film-coated tablets are white to off white capsule shaped, film coated tablet. 
Irbesartan Teva 150 mg filmom obložene tablete Bijela do gotovo bijela, filmom obložena tableta u obliku kapsule.
IRMA 2 was a placebo-controlled double blind morbidity study in 
IDNT je bila dvostruko slijepa,
Hypertension and type 2 diabetes with renal disease 
Hipertenzivni bolesnici sa šećernom bolesti tipa 2 i bubrežnom bolesti
Package leaflet: information for the user Irbesartan Teva 75 mg Film-Coated Tablets 
Uputa o lijeku: Informacija za korisnika Irbesartan Teva 75 mg filmom obložene tablete irbesartan
Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. 
4.9 Predoziranje Iskustvo je pokazalo da nije bilo toksičnog djelovanja irbesartana u odraslih ljudi koji su bili izloženi dozama do 900 mg/dan tijekom 8 tjedana.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine. 
Nuspojave možete prijaviti izravno putem nacionalnog sustava prijave nuspojava: navedenog u Dodatku V*..
Irbesartan Teva 75 mg film-coated tablets 
Irbesartan Teva 75 mg filmom obložene tablete
A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis (see section 4.4). 
U bolesnika na hemodijalizi treba razmotriti započinjanje liječenja nižom početnom dozom od 75 mg (vidjeti dio
Package leaflet: information for the user Irbesartan Teva 300 mg Film-Coated Tablets 
Uputa o lijeku: Informacija za korisnika Irbesartan Teva 300 mg filmom obložene tablete irbesartan
The other side of the tablet debossed with number “7465”. 
Na drugoj strani tablete je utisnut broj “7465”.
Irbesartan Teva 75 mg film-coated tablets Each film-coated tablet contains 75 mg of irbesartan 
Irbesartan Teva 75 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 75 mg irbesartana
Package leaflet: information for the user Irbesartan Teva 150 mg Film-Coated Tablets 
Uputa o lijeku: Informacija za korisnika Irbesartan Teva 150 mg filmom obložene tablete irbesartan
Irbesartan Teva 150 mg film-coated tablets Each film-coated tablet contains 150 mg of irbesartan 
Irbesartan Teva 150 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 150 mg irbesartana
Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum creatinine, and albumin excretion rate were assessed for treatment effect. 
Za djelotvornost liječenja ocjenjivane su podskupine prema spolu, rasi, dobi, trajanju šećerne bolesti, početnom krvnom tlaku, serumskom kreatininu i izlučivanju albumina.U podskupinama žena i pripadnika crne rase, koji su činili 32% odnosno 26% ukupne populacije u studiji, nisu bili vidljivi povoljni učinci na bubrege, premda to intervali pouzdanosti nisu isključivali.
Irbesartan Teva 75 mg film-coated tablets Irbesartan 
Irbesartan Teva 75 mg filmom obložene tablete irbesartan
The “Irbesartan Diabetic Nephropathy Trial (IDNT)” shows that irbesartan decreases the progression of renal disease in patients with chronic renal insufficiency and overt proteinuria. 
Hipertenzija i šećerna bolest tipa 2 s bubrežnom bolesti Klinička studija „Ispitivanje irbesartana u bolesnika s dijabetičkom nefropatijom“ (Irbesartan Diabetic Nephropathy Trial, IDNT) pokazuje da irbesartan smanjuje progresiju bubrežne bolesti u bolesnika s kroničnom bubrežnom insuficijencijom i manifestnom proteinurijom.
If you take more Irbesartan Teva than you should 
Ako uzmete više Irbesartana
Irbesartan Teva 300 mg film-coated tablets Each film-coated tablet contains 300 mg of irbesartan 
Irbesartan Teva 300 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 300 mg irbesartana
Irbesartan Teva 300 mg film-coated tablets EU/1/09/576/027 7 tablets EU/1/09/576/028 14 tablets 
Irbesartan Teva 300 mg filmom obložene tablete EU/1/09/576/027 7 tableta
Cardiac disorders Uncommon: tachycardia Vascular disorders Common: 
Srčani poremećaji Manje često: tahikardija Krvožilni poremećaji Često: ortostatska hipotenzija*
If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Irbesartan Teva” and “Warnings and precautions”). 
“Nemojte uzimati Irbesartan Teva” i “Upozorenja i mjere opreza”).
Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mm Hg or a 10 mm Hg reduction in systolic pressure if baseline was > 160 mm Hg. 
diuretike, beta blokatore, alfa blokatore) kako bi postigli unaprijed definirani krvni tlak od ≤ 135/85
Irbesartan Teva 300 mg film-coated tablets Irbesartan 
Irbesartan Teva 300 mg filmom obložene tablete irbesartan
Irbesartan Teva 150 mg film-coated tablets Irbesartan 
Irbesartan Teva 150 mg filmom obložene tablete irbesartan
Metabolism and nutrition disorders Not known: 
Poremećaji metabolizma i prehrane
Irbesartan Teva 75 mg film-coated tablets Irbesartan Teva 150 mg film-coated tablets Irbesartan Teva 300 mg film-coated tablets 
Irbesartan Teva 150 mg filmom obložene tablete Irbesartan Teva 300 mg filmom obložene tablete
Irbesartan Teva is for oral use. 
Teva je namijenjen za primjenu kroz usta.
EU/1/09/576/025 50 x 1 tablet (unit dose) EU/1/09/576/026 56 x 1 tablet (unit dose) EU/1/09/576/041 28 tablets (calendar pack) 
EU/1/09/576/025 50 x 1 tableta (jedinična doza) EU/1/09/576/026 56 x 1 tableta (jedinična doza) EU/1/09/576/041 28 tableta (kalendarsko pakiranje)
EU/1/09/576/038 50 x 1 tablet (unit dose) EU/1/09/576/039 56 x 1 tablet (unit dose) EU/1/09/576/042 28 tablets (calendar pack) 
EU/1/09/576/038 50 x 1 tableta (jedinična doza) EU/1/09/576/039 56 x 1 tableta (jedinična doza) EU/1/09/576/042 28 tableta (kalendarsko pakiranje)
Irbesartan Teva is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section). 
Ne smijete ga uzimati nakon trećeg mjeseca trudnoće jer može ozbiljno naškoditi Vašem djetetu ako ga uzimate u tom stadiju (vidjeti dio o trudnoći).
Irbesartan Teva 150 mg film-coated tablets 
Irbesartan Teva 150 mg filmom obložene tablete
Irbesartan Teva 300 mg film-coated tablets 
Irbesartan Teva 300 mg filmom obložene tablete
Each film-coated tablet contains 75 mg irbesartan 
NAVOĐENJE DJELATNE(IH) TVARI Jedna filmom obložena tableta sadrži 75 mg irbesartana
TEVA UK Ltd Brampton Road Hampden Park Eastbourne, East Sussex BN22 9AG UK 
Mađarska TEVA UK Ltd Brampton Road
Irbesartan 75 mg film-coated tablets are white to off white capsule shaped, film coated tablet. 
Kako Irbesartan Teva izgleda i sadržaj pakiranja Irbesartan 75 mg filmom obložene tablete su bijele do gotovo bijele filmom obložene tablete u obliku kapsule.
fatigue Uncommon: chest pain 
Manje često: kašalj
Each film-coated tablet contains 150 mg irbesartan 
NAVOĐENJE DJELATNE(IH) TVARI Jedna filmom obložena tableta sadrži 150 mg irbesartana
Due date 
Doze od
Irbesartan 300 mg film-coated tablets are white to off white capsule shaped, film coated tablet. 
Kako Irbesartan Teva izgleda i sadržaj pakiranja Irbesartan 300 mg filmom obložene tablete su bijele do gotovo bijele filmom obložene tablete u obliku kapsule. na jednoj strani tablete je utisnut broj “93”.
hyperkalaemia Nervous system disorders Common: 
Poremećaji živčanog sustava
The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated. 
poput rifampicina na farmakokinetiku irbesartana.
Detailed information on Irbesartan Teva is available on the European Medicines Agency web site: http://www.ema.europa.eu/ 
(EMA) http://www.ema.europa.eu/
In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan (56.2 %) and the placebo groups (56.5 %). 
U placebom kontroliranim kliničkim ispitivanjima, koja su provedena na bolesnicima s hipertenzijom, ukupna incidencija štetnih događaja nije se razlikovala između skupine koja je uzimala irbesartan
EU/1/09/576/012 50 x 1 tablet (unit dose) EU/1/09/576/013 56 x 1 tablet (unit dose) EU/1/09/576/040 28 tablets (calendar pack) 
EU/1/09/576/012 50 x 1 tableta (jedinična doza) EU/1/09/576/013 56 x 1 tableta (jedinična doza)
Tablet Core: 
Oštećena funkcija jetre
Pliva Hrvatska d.o.o Tel: +385 13720000 
Teva Pharmaceuticals Polska Sp. z o.o. Tel.: +48 223459300
Danmark 
Finnland
Each film-coated tablet contains 300 mg irbesartan 
NAVOĐNJE DJELATNE(IH) TVARI Jedna filmom obložema tableta sadrži 300 mg irbesartana.
If you take certain painkillers, called non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced. 
Učinak irbesartana može se smanjiti ako uzimate lijekove protiv bolova poznate kao nesteroidni protuupalni lijekovi.
Uncommon (may affect up to 1 in 100 people): heart rate increased, flushing, cough, diarrhoea, indigestion/heartburn, sexual dysfunction (problems with sexual performance), chest pain. 
proljev, probavne tegobe/žgaravica, problemi sa seksualnom funkcijom, bol u prsištu.
Date of first authorisation: 08/07/2014 Date of latest renewal: 
Datum prvog odobrenja: 08/07/2014 Datum posljednjeg produljenja odobrenja:
ATCvet code: QI09AL01. 
ATCvet kod: QI09AL01
* RP - relative potency (ELISA). 
* RP - Relativna potentnost (ELISA).
17170 Amer (Girona) SPAIN 
17170 Amer (Girona) Španjolska
Porcine parvovirus: from the beginning of the gestation period. 
Parvovirus svinja: od početka gestacijskog razdoblja.
A single injection should be given 2-3 weeks prior to each subsequent mating (approximately every 6 months). 
Po jedna injekcija se mora dati 2-3 tjedna prije svakog sljedećeg parenja (približno svakih 6 mjeseci).
Revaccination should be performed prior to each gestation, see section 4.9. 
Docjepljivanje se mora provesti prije svake gestacije, pogledajte odlomak 4.9.
Duration of immunity: 
Trajanje imuniteta:
Pigs from 6 months of age which have not been previously vaccinated with the product should be given two injections with an interval of 3-4 weeks. 
Svinje starije od 6 mjeseci koje nisu prethodno cijepljene ovim cjepivom trebaju primiti dvije injekcije u razmaku od 3-4 tjedna.
E. rhusiopathiae: three weeks after completion of the basic vaccination scheme. 
E. rhusiopathiae: tri tjedna nakon završetka sheme osnovnog cijepljenja.
Vaccinate healthy animals only. 
Cijepite samo zdrave životinje.
The second injection should be administered 3-4 weeks before mating. 
Druga injekcija se mora dati 3-4 tjedna prije parenja.
The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009. 
Djelatna tvar koja se sastoje od tvari biološkog podrijetla, namijenjena je za stvaranje aktivne imunosti, na koje se ne primjenjuju odredbe Uredbe (EK) br. 470/2009.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP. 
Ovaj veterinarski medicinski proizvod se ne smije koristiti nakon isteka roka trajanja koji je istaknut na oznaci iza natpisa EXP.
In case of adverse reactions following accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 
U slučaju nuspojava nakon slučajnog samoinjiciranja odmah potražite medicinski savjet i liječniku pokažite uputu o VMP ili oznaku.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the product mentioned above. 
Ne postoje dostupni podaci o neškodljivosti i učinkovitosti ovog cjepiva kada se primjenjuje s bilo kojim drugim veterinarsko-medicinskim proizvodom osim za gore navedeni proizvod.
Sodium hydroxide Water for injections 
Natrijev hidroksid Voda za injekcije
Do not use in case of hypersensitivity to the active substances, to the adjuvants or to any of the excipients. 
Ne primjenjivati u slučaju preosjetljivosti na djelatne tvari, na adjuvanse ili na bilo koju od pomoćnih tvari.
Administer one dose of 2 ml by intramuscular injection in the neck muscles according to the following schedule: 
Primijenite jednu dozu od 2 ml intramuskularno u vratne mišiće prema sljedećem rasporedu:
** IE50% - Inhibition ELISA 50%. 
** IE50 % inhibicija ELISA - 50%.
A single dose (2 ml) of the mixed vaccines should be injected within a period of 2 hours via intramuscular use. 
Jedna doza (2 ml) miješanog cjepiva treba se injicirati intramuskularno u roku od 2 sata.
HIPRA POLSKA Sp.z.o.o. 
HIPRA POLSKA Sp.z.o.o. Tel.
Very rare adverse reactions: - Anaphylactic-type reactions have been reported in spontaneous reports and appropriate symptomatic treatment is recommended. 
- Reakcije anafilaktičkog tipa zabilježene su u spontanim izvješćima i preporučuje se odgovarajuća simptomatska terapija.
LABORATORIOS HIPRA, S.A. Carretera C-63, km 48.300, Polígono Industrial El Rieral 17170 Amer (Girona) SPAIN 
LABORATORIOS HIPRA, S.A. Carretera C-63, km 48.300, Polígono Industrial El Rieral
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with UNISTRAIN PRRS (where this vaccine is authorised) and administered at one injection site. 
Postoje raspoloživi podaci o neškodljivosti i učinkovitosti koji pokazuju da se ovo cjepivo može miješati s UNISTRAIN PRRS (tamo gdje je to cjepivo odobreno) i primijeniti na isto mjesto injiciranja.
Pharmacotherapeutic group: Immunologicals for suidae, Inactivated viral and bacterial vaccines. 
Farmakoterapijska skupina: Imunološki pripravci za svinje, inaktivirana virusna i bakterijska cjepiva.
Name and address of the manufacturers of the biological active substances: 
Naziv i adresa proizvođača biološki djelatnih tvari:
The vials are closed with a rubber stopper and aluminium cap. 
Bočice su zatvorene gumenim čepom i aluminijskim zatvaračem.
ERYSENG PARVO suspension for injection for pigs 
ERYSENG PARVO suspenzija za injekcije za svinje
Disodium phosphate dodecahydrate Ginseng 
Dinatrijev fosfat dodekahidrat Ginseng
Polyethylene (PET) bottles of 20, 50, 100 and 250 ml. 
Polietilenske (PET) boce od 20, 50, 100 i 250 ml.
Porcine parvovirus: vaccination provides foetal protection for the duration of gestation. 
Parvovirus svinja: cijepljenje pruža zaštitu fetusa tijekom gestacije.
However, the duration of immunity of the Erysipelas component following mixed use has not been investigated. 
Međutim, trajanje imunosti za komponentu protiv vrbanca nakon miješane primjene još nije ispitano.
E. rhusiopathiae: vaccination protects against swine erysipelas until the time of the recommended revaccination (approximately six months after the basic vaccination scheme), see section 4.9. 
E. rhusiopathiae: cijepljenje štiti od vrbanca svinja sve do trenutka kada se preporučuje docjepljivanje (približno šest mjeseci nakon sheme osnovnog cijepljenja), pogledajte odlomak 4.9.